Clinical Trial Update: PIC1 Injection Therapy for Relapsed/Refractory B-NHL [Phase 1]

View source ↗

Summary

Phase 1 clinical trial of PIC1 Injection Therapy for relapsed/refractory B-cell non-Hodgkin lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• PIC1

Snippet

Sponsor: Chongqing Precision Biotech Co., Ltd | Conditions: Non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING